In vivo SELEX of bone targeting aptamer in prostate cancer bone metastasis model

Purpose PB is one of the most severe complications of late stage prostate cancer and negatively impacts patient quality of life. A major challenge for the treatment of cancer bone metastasis is the management of efficient drug delivery to metastatic bone lesion. We aimed to explore the use of aptamers as promising tools to develop a targeted drug delivery system for PBs. Materials and methods In vivo SELEX was applied to identify bone targeting aptamer in a mouse model with PBs. Results The aptamer (designated as “PB”) with the highest bone targeting frequency in mice bearing PC3 PB was selected for further analysis. The PB aptamer specifically targeted modulated endothelial cells in response to cancer cells in the bones of mice bearing PC3 PBs. The targeting efficiency of the PB aptamer conjugated to gold particles was verified in vivo. Conclusion This investigation highlights the promise of in vivo SELEX for the discovery of bone targeting aptamers for use in drug delivery.

[1]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[2]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[3]  Xiaojuan He,et al.  Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders , 2016, International journal of molecular sciences.

[4]  K. Hirata,et al.  Targeted Disruption of Endothelial Cell-selective Adhesion Molecule Inhibits Angiogenic Processes in Vitro and in Vivo* , 2003, Journal of Biological Chemistry.

[5]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  Stephen C Cowin,et al.  Blood and interstitial flow in the hierarchical pore space architecture of bone tissue. , 2015, Journal of biomechanics.

[7]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[8]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[9]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[10]  Yu Cao,et al.  Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference–based bone anabolic strategy , 2015, Nature Medicine.

[11]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[12]  B. Sullenger,et al.  In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9 , 2016, Molecular therapy. Nucleic acids.

[13]  Enzo Di Fabrizio,et al.  Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy , 2012, International journal of nanomedicine.

[14]  Miguel Martín,et al.  Denosumab for the treatment of bone metastases in advanced breast cancer. , 2013, Breast.

[15]  Youli Zu,et al.  Aptamers and their applications in nanomedicine. , 2015, Small.

[16]  P. Francis,et al.  Strategies for the discovery and development of therapies for metastatic breast cancer , 2012, Nature Reviews Drug Discovery.

[17]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[18]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[19]  J. Folkman,et al.  Toward an Understanding of Angiogenesis: Search and Discovery , 2015, Perspectives in biology and medicine.

[20]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[21]  W. Aird.  Endothelial cell heterogeneity , 2003, Critical care medicine.

[22]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[23]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[24]  K. Mertz,et al.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis , 2014, Nature.

[25]  A. Lluch,et al.  Zoledronic acid in the treatment of metastatic breast cancer , 2014, Anti-cancer drugs.

[26]  Dai Fukumura,et al.  Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. , 2007, Microvascular research.

[27]  Y. Nam,et al.  Functional Nanostructures for Effective Delivery of Small Interfering RNA Therapeutics , 2014, Theranostics.